SpringWorks Therapeutics Inc (NASDAQ: SWTX) kicked off on Tuesday, down -1.61% from the previous trading day, before settling in for the closing price of $49.84. Over the past 52 weeks, SWTX has traded in a range of $28.21-$62.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 663.47%. While this was happening, its average annual earnings per share was recorded 34.71%. With a float of $70.33 million, this company’s outstanding shares have now reached $74.40 million.
Let’s determine the extent of company efficiency that accounts for 368 employees. In terms of profitability, gross margin is 93.07%, operating margin of -145.17%, and the pretax margin is -134.73%.
SpringWorks Therapeutics Inc (SWTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of SpringWorks Therapeutics Inc is 6.15%, while institutional ownership is 105.71%. The most recent insider transaction that took place on Mar 03 ’25, was worth 1,084,592. In this transaction Chief Operating Officer of this company sold 20,000 shares at a rate of $54.23, taking the stock ownership to the 169,712 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Executive Officer sold 49,000 for $54.24, making the entire transaction worth $2,657,656. This insider now owns 954,869 shares in total.
SpringWorks Therapeutics Inc (SWTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.71% per share during the next fiscal year.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) Trading Performance Indicators
Take a look at SpringWorks Therapeutics Inc’s (SWTX) current performance indicators. Last quarter, stock had a quick ratio of 3.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.48, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of SpringWorks Therapeutics Inc (SWTX)
Looking closely at SpringWorks Therapeutics Inc (NASDAQ: SWTX), its last 5-days average volume was 1.72 million, which is a drop from its year-to-date volume of 2.63 million. As of the previous 9 days, the stock’s Stochastic %D was 48.80%. Additionally, its Average True Range was 3.15.
During the past 100 days, SpringWorks Therapeutics Inc’s (SWTX) raw stochastic average was set at 61.65%, which indicates a significant increase from 21.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.17% in the past 14 days, which was lower than the 77.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.86, while its 200-day Moving Average is $38.82. However, in the short run, SpringWorks Therapeutics Inc’s stock first resistance to watch stands at $50.01. Second resistance stands at $50.98. The third major resistance level sits at $51.64. If the price goes on to break the first support level at $48.38, it is likely to go to the next support level at $47.72. Now, if the price goes above the second support level, the third support stands at $46.75.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) Key Stats
The company with the Market Capitalisation of 3.67 billion has total of 74,936K Shares Outstanding. Its annual sales at the moment are 191,590 K in contrast with the sum of -258,130 K annual income. Company’s last quarter sales were recorded 61,550 K and last quarter income was -77,300 K.
